Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
Holding BPMC?
Track your performance easily
Earnings Data
Report Date
Feb 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.7Last Year’s EPS
-$1.82Same Quarter Last Year
Moderate Buy
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 30, 2024
|% Change Since: 8.08%
|Next Earnings Date:Feb 13, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial and operational performance for Blueprint Medicines, highlighted by significant revenue growth and strategic advancements in the pipeline. Despite some challenges with pricing dynamics in the international markets and potential impacts of free drug policies, the overall outlook remains positive with a focus on sustainable growth and innovation.Company Guidance
During the Blueprint Medicines Q3 2024 earnings call, the company reported significant growth in AYVAKIT revenue, raising their full-year revenue guidance to between $475 million and $480 million. This strong performance was driven by $128.2 million in net product revenue for the quarter, with $113.1 million from the U.S. and $15.1 million from international markets, marking a 137% increase year-over-year. The company highlighted AYVAKIT's $2 billion peak revenue potential, supported by new patient starts, low discontinuation rates, and strong compliance. Additionally, Blueprint is making strides in international markets, particularly in Germany, and anticipates further geographic expansion in 2025. The company also discussed ongoing development efforts for BLU-808, a wild-type KIT inhibitor, and elenestinib, as part of their strategic focus on driving long-term growth in the mast cell portfolio. Blueprint reported a stable gross-to-net margin in the mid-80s and a significant drop in cash burn, reinforcing their path to financial sustainability.AYVAKIT Revenue Growth
AYVAKIT achieved $128.2 million in net product revenue in Q3 2024, marking a 137% increase year-over-year. The company raised its revenue guidance, expecting to achieve $475 million to $480 million in net product revenue for 2024.
Strong International Performance
The international team delivered strong results with significant growth in advanced SM across several geographies, particularly in Germany. The international business is expected to break even by the end of the year.
Financial Position
Blueprint Medicines reported $882.4 million in cash on hand at the end of Q3 2024, with a significant decline in cash burn and a path to financial sustainability.
Pipeline Progress
The company is advancing its mast cell portfolio with the initiation of the registration-enabling Part 2 of the HARBOR study by year-end and ongoing Phase I study of BLU-808.
---
BPMC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BPMC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $83.40 | $89.24 | +7.00% |
| Aug 01, 2024 | $108.30 | $100.29 | -7.40% |
| May 02, 2024 | $94.86 | $107.00 | +12.80% |
| Feb 15, 2024 | $76.80 | $87.57 | +14.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Blueprint Medicines (BPMC) report earnings?
Blueprint Medicines (BPMC) is schdueled to report earning on Feb 13, 2025, TBA Not Confirmed.
What is Blueprint Medicines (BPMC) earnings time?
Blueprint Medicines (BPMC) earnings time is at Feb 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BPMC EPS forecast?
BPMC EPS forecast for the fiscal quarter 2024 (Q4) is -$0.7.
---